Aktis Oncology, Inc. (AKTS)

Aktis Oncology is a clinical-stage biotech generating exceptional 111.4% revenue growth, likely driven by early pipeline commercialization or milestone activity, and commands near-unanimous Strong Buy conviction from 7 analysts with zero dissent. The analyst consensus price target of $34.42 implies ~38% upside from current levels, reflecting high confidence in the oncology pipeline's differentiation. The primary risk is the company's loss-making status with a negative forward P/E, making it entirely dependent on pipeline execution and external capital to sustain operations.

• Clinical trial readouts or Phase data releases for lead oncology program(s) that could serve as near-term value inflection points.
• Revenue continuation or acceleration above the current 111.4% YoY growth rate, validating commercial or partnership momentum in upcoming quarterly reports.
• Potential partnership, licensing deal, or non-dilutive funding announcement that extends the cash runway and de-risks the balance sheet.

• Ongoing cash burn with a deeply negative forward P/E (-11.7x) creates significant dilution risk if the company must raise equity capital at or near current prices.
• Zero EPS beats in the last 2 quarters raises concern about management's ability to meet near-term financial expectations, which could erode analyst confidence.
• Clinical-stage concentration risk: failure or delay of a key pipeline asset in a binary readout event could result in a severe share price decline, as the entire valuation is pipeline-dependent.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →